VolitionRx Limited

0.49
-0.01 (-2.00%)
At close: Apr 17, 2025, 3:59 PM
0.48
-1.58%
Pre-market: Apr 21, 2025, 06:06 AM EDT

Company Description

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide.

It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.

The company operates Nucleosomics a technology platform for blood test.

VolitionRx Limited is based in Austin, Texas.

VolitionRx Limited
VolitionRx Limited logo
Country United States
IPO Date Mar 2, 2012
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 85
CEO Cameron Reynolds MBA

Contact Details

Address:
13215 Bee Cave Parkway
Austin, Texas
United States
Website https://www.volition.com

Stock Details

Ticker Symbol VNRX
Exchange AMEX
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000093314
CUSIP Number 928661107
ISIN Number US9286611077
Employer ID 91-1949078
SIC Code 2835

Key Executives

Name Position
Cameron Reynolds MBA Founder, Chief Executive Officer, President & Director
Dr. Salvatore Thomas Butera DVM Chief Executive Officer of Volition Veterinary Diagnostics Development LLC
Dr. Gaetan Michel Ph.D. Chief Operating Officer
Terig Hughes Chief Financial Officer & Treasurer
Dr. Andrew Retter MBBS Chief Medical Officer
Dr. Jacob Vincent Micallef MBA, Ph.D. Chief Scientific Officer
Gael Forterre M.B.A. Chief Commercial Officer
Louise Batchelor Day Group Chief Marketing & Communications Officer
Nicholas Plummer Group General Counsel
Sharon Ballesteros U.S. Head of Quality & Development Process

Latest SEC Filings

Date Type Title
Apr 16, 2025 RW Filing
Apr 11, 2025 S-3/A [Amend] Filing
Apr 07, 2025 SCHEDULE 13G/A [Amend] Filing
Apr 04, 2025 8-K Current Report
Apr 04, 2025 S-1 Filing
Apr 04, 2025 PRE 14A Filing
Mar 31, 2025 10-K Annual Report
Mar 31, 2025 8-K Current Report
Mar 27, 2025 4 Filing
Mar 27, 2025 4 Filing